Company intelligence / Profile preview

Charleston Laboratories, Inc.

Jupiter, Florida, United Statescharlestonlabs.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Charleston Laboratories completed two Phase 3 clinical trials for their lead product CL-108, a novel bi-layered tablet containing hydrocodone, acetaminophen, and promethazine. The company has resubmitted an NDA for CL-108. The first Phase 3 trial was conducted in patients following bunionectomy surgery, and the second was an open-label safety study in patients with osteoarthritis of the knee or hip.

Therapeutic areas: GastroenterologyOncologyNeurology
Modalities: Small moleculescombination drugs
Industry: Biotech

Drug pipeline

7 assets

CL-H2T

Preclinical

6 more assets in the full pipeline.

Request access →

Partnerships

Daiichi Sankyo, Inc.

Beyond the preview

Go deeper on Charleston Laboratories, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Charleston Laboratories, Inc..

Explore the full profile